Sign up
Pharma Capital

'Customer data validates strategy' for cancer diagnostic, says ANGLE PLC boss Andrew Newland

Andrew Newland, founder of ANGLE PLC (LON:AGL, OTCQX:ANPCY) runs Proactive through research carried out by the University of Athens and Attikon University Hospital which has found that their Parsortix system out-performs existing technology and, for the first time, is able to harvest head and neck cancer cells from patient blood for analysis.

 

View full AGL profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.